Cargando…

Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis

BACKGROUND: Postmenopausal osteoporosis (PMOP) is the focus and difficult problem in the world at present, and we found that Chinese patent medicine(CPM) shown a more miraculous effect. Many kinds of Chinese patent medicine have been proved to be effective in the treatment of this disease, but it is...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Hongqiang, Zhao, Jifeng, Wang, Jiahao, Li, Chuancheng, Jiang, Zhenyuan, Yao, Junpeng, Zhang, Xiao, Wu, Jianlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572013/
https://www.ncbi.nlm.nih.gov/pubmed/33080732
http://dx.doi.org/10.1097/MD.0000000000022734
_version_ 1783597260839321600
author An, Hongqiang
Zhao, Jifeng
Wang, Jiahao
Li, Chuancheng
Jiang, Zhenyuan
Yao, Junpeng
Zhang, Xiao
Wu, Jianlin
author_facet An, Hongqiang
Zhao, Jifeng
Wang, Jiahao
Li, Chuancheng
Jiang, Zhenyuan
Yao, Junpeng
Zhang, Xiao
Wu, Jianlin
author_sort An, Hongqiang
collection PubMed
description BACKGROUND: Postmenopausal osteoporosis (PMOP) is the focus and difficult problem in the world at present, and we found that Chinese patent medicine(CPM) shown a more miraculous effect. Many kinds of Chinese patent medicine have been proved to be effective in the treatment of this disease, but it is still unclear which kind of Chinese patent medicine has the best effect. Therefore, we propose a network meta-analysis (NMA) protocol to observe the efficacy of various CPM for this disease and provide guidance for clinical practice. METHODS: We will use the NMA method to complete this study. First, all the randomized controlled trials of CPM or CPM combined with western medicine in the treatment of PMOP were collected by searching all online Chinese and English databases. The information time limit is from the establishment of the database to August 30, 2020. Then 2 staff members will sift through all the literature and analyze the data using Stata and Winbugs. RESULTS: Through this analysis, we will observe and rank the clinical effects of different CPM for PMOP. The main evaluation indexes include: New fracture, Quality of life, Severe side effects, Death from all causes. Secondary outcome indicators include Bone Mineral density, clinical efficiency, and some laboratory indicators, such as estradiol, serum calcium, serum, etc. CONCLUSION: This study will rank the therapeutic effects of various proprietary Chinese medicines in the treatment of PMOP, which will be helpful in improving the PMOP treatment regimen. INPLASY registration number: INPLASY202090047.
format Online
Article
Text
id pubmed-7572013
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75720132020-10-29 Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis An, Hongqiang Zhao, Jifeng Wang, Jiahao Li, Chuancheng Jiang, Zhenyuan Yao, Junpeng Zhang, Xiao Wu, Jianlin Medicine (Baltimore) 3800 BACKGROUND: Postmenopausal osteoporosis (PMOP) is the focus and difficult problem in the world at present, and we found that Chinese patent medicine(CPM) shown a more miraculous effect. Many kinds of Chinese patent medicine have been proved to be effective in the treatment of this disease, but it is still unclear which kind of Chinese patent medicine has the best effect. Therefore, we propose a network meta-analysis (NMA) protocol to observe the efficacy of various CPM for this disease and provide guidance for clinical practice. METHODS: We will use the NMA method to complete this study. First, all the randomized controlled trials of CPM or CPM combined with western medicine in the treatment of PMOP were collected by searching all online Chinese and English databases. The information time limit is from the establishment of the database to August 30, 2020. Then 2 staff members will sift through all the literature and analyze the data using Stata and Winbugs. RESULTS: Through this analysis, we will observe and rank the clinical effects of different CPM for PMOP. The main evaluation indexes include: New fracture, Quality of life, Severe side effects, Death from all causes. Secondary outcome indicators include Bone Mineral density, clinical efficiency, and some laboratory indicators, such as estradiol, serum calcium, serum, etc. CONCLUSION: This study will rank the therapeutic effects of various proprietary Chinese medicines in the treatment of PMOP, which will be helpful in improving the PMOP treatment regimen. INPLASY registration number: INPLASY202090047. Lippincott Williams & Wilkins 2020-10-16 /pmc/articles/PMC7572013/ /pubmed/33080732 http://dx.doi.org/10.1097/MD.0000000000022734 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3800
An, Hongqiang
Zhao, Jifeng
Wang, Jiahao
Li, Chuancheng
Jiang, Zhenyuan
Yao, Junpeng
Zhang, Xiao
Wu, Jianlin
Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis
title Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis
title_full Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis
title_fullStr Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis
title_full_unstemmed Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis
title_short Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis: A protocol for systematic review and network meta-analysis
title_sort comparison of efficacy and safety of chinese patent medicine in the treatment of postmenopausal osteoporosis: a protocol for systematic review and network meta-analysis
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572013/
https://www.ncbi.nlm.nih.gov/pubmed/33080732
http://dx.doi.org/10.1097/MD.0000000000022734
work_keys_str_mv AT anhongqiang comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis
AT zhaojifeng comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis
AT wangjiahao comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis
AT lichuancheng comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis
AT jiangzhenyuan comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis
AT yaojunpeng comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis
AT zhangxiao comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis
AT wujianlin comparisonofefficacyandsafetyofchinesepatentmedicineinthetreatmentofpostmenopausalosteoporosisaprotocolforsystematicreviewandnetworkmetaanalysis